
AOBiome is a biotech company that's been making waves in the field of microbiome research. Founded in 2015 by Dr. Patrick Frank and Dr. Louis Brenner, AOBiome is dedicated to harnessing the power of beneficial microbes to improve human health.
AOBiome's research has focused on the beneficial microbes that produce ammonia, specifically the genus Azotobacter. These microbes play a crucial role in nitrogen fixation, a process that's essential for plant growth and development.
The company's innovative approach involves developing novel therapeutics and products that target the microbiome to treat a range of conditions, including skin diseases and inflammatory disorders. By leveraging the unique properties of these beneficial microbes, AOBiome aims to revolutionize the way we approach microbiome-based treatments.
Expand your knowledge: Bain & Company
Research and Development
AOBiome is a biotech company that's making waves in the world of gut health. They're focused on developing innovative products and treatments using the latest research and technology.
AOBiome's research is centered around the human microbiome, with a focus on understanding the complex relationships between microbes and the body. This involves studying the trillions of microorganisms that live inside and on our bodies.
Related reading: B Capital
Their scientists are working to identify new ways to harness the power of the microbiome to improve human health. This includes developing treatments for conditions like eczema and psoriasis.
AOBiome's research has led to the development of a proprietary blend of microbiome-derived compounds. These compounds have shown promise in reducing inflammation and promoting healing in the skin.
Their scientists are also exploring the use of microbiome-derived compounds to treat other conditions, such as inflammatory bowel disease. This involves studying the effects of these compounds on the gut microbiome and immune system.
AOBiome's research is driven by a deep understanding of the microbiome and its role in human health. They're committed to using this knowledge to develop innovative treatments and products that can improve people's lives.
Locations and Entities
AOBiome is a company with a presence in the United States, where it is incorporated as Aobiome Llc with a CIN of 461601854.
The company has a relatively small team, with 8 employees as of December 31, 2022.
AOBiome is not the only company in the field of therapeutics, and it ranks 115th in a list of top companies in this space.
Here are some key facts about AOBiome's ranking and funding:
Entities Associated with Aobime

AOBiome, the company behind AOBiome, is a therapeutics company that focuses on restoring immune functionality to treat inflammatory skin conditions.
AOBiome Llc, the primary legal entity associated with AOBiome, was incorporated on December 31, 1999.
AOBiome Llc is an active entity in the United States, with a CIN (Company Identification Number) of 461601854.
The company has a relatively small team, with only 8 employees as of December 31, 2022.
Clinical Trials
AOBiome is developing topical biologics for the treatment of inflammatory conditions.
The company started its Phase 2 clinical trial for adult acne in 2015. AOBiome is also conducting Phase I trials for related therapies in allergic rhinitis and eczema.
Their prospective interventional study on the link between a bacteria-infused topical spray and hypertension showed a strong reduction in blood pressure. This was an unexpected finding, as the company initially only expected to treat acne.
AOBiome is also exploring preclinical trials for wound healing, migraines, and thermoregulation.
Locations
Our primary location is at 125 Cambridge Park Dr, 5th Floor, Cambridge, Massachusetts 02140, US. You can get directions to this spot.
If you need to visit us, the address is 125 Cambridge Park Dr, 5th Floor, Cambridge, Massachusetts 02140, US.
Discover more: Massachusetts Arms Company
Financial Information
AOBiome has raised a total of $33.7M in funding over 4 rounds. This funding has helped the company grow and expand its operations.
The company's first funding round was on March 21, 2013. It was a significant milestone for AOBiome, marking the beginning of its journey to success.
AOBiome has a total of 5 institutional investors, including Hedgewood, Wakestream Ventures, and Neoteny. These investors have been instrumental in providing the necessary funding for the company's growth.
The company's latest funding round was a Series C round on January 5, 2017, for $30M. This funding round was led by ICarbonX, and it marked a significant increase in AOBiome's valuation.
Here is a breakdown of AOBiome's funding rounds:
Featured Images: pexels.com


